Table 3.
Pharmacokinetic Parameters of Frovatriptan in Whole Blood by Gender After Ascending Single-Dose Oral Administration
| Parameter | 2.5 mg | 5 mg | 10 mg | ||||
|---|---|---|---|---|---|---|---|
| Male | Female | Male | Female | Male | Female | ||
| (n = 6) | (n = 6) | (n = 6) | (n = 6) | (n = 6) | (n = 6) | ||
| Cmax, ng/mL | Mean | 4.88 | 7.66** | 8.04 | 12.08 | 16.56 | 18.13 |
| SD | 1.67 | 1.01 | 4.23 | 1.89 | 10.32 | 1.73 | |
| AUClast, h·ng/mL | Mean | 59.17 | 125.87*** | 116.02 | 205.62* | 232.85 | 341.95 |
| SD | 31.16 | 19.93 | 67.40 | 49.55 | 164.62 | 39.97 | |
| AUCinf, h·ng/mL | Mean | 63.70 | 135.71*** | 124.49 | 226.14* | 249.26 | 374.98 |
| SD | 31.94 | 23.79 | 73.08 | 60.63 | 178.07 | 56.39 | |
| Tmax, h | Median | 2.75 | 3.25 | 3.00 | 3.75 | 3.00 | 4.50 |
| Min, Max | 1.50, 3.50 | 2.50, 5.00 | 2.00, 4.00 | 2.50, 5.00 | 2.50, 4.00 | 3.00, 6.00 | |
| t1/2, h | Mean | 24.59 | 28.34 | 28.08 | 30.98 | 28.80 | 29.64 |
| SD | 6.36 | 2.59 | 3.46 | 4.20 | 2.21 | 4.36 | |
| Vz/F, L | Mean | 1670.04 | 771.23* | 2068.34 | 1025.12 | 2193.43 | 1143.87 |
| SD | 738.46 | 149.78 | 1040.97 | 216.53 | 1064.18 | 97.96 | |
| CLz/F, L/h | Mean | 49.64 | 18.95* | 53.29 | 23.27 | 53.28 | 27.16* |
| SD | 28.96 | 3.67 | 32.82 | 5.31 | 26.25 | 3.95 | |
Notes: *P < 0.05, **P < 0.01, ***P < 0.001.